Large-scale testing (Phase 3)Active Not RecruitingNCT05456191
What this trial is testing
Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
Who this might be right for
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Novartis Pharmaceuticals 568